EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieOpen Access · CC BY-NC 4.0

Pharmacokinetics and pharmacodynamics of intravenous and oral (S)‐ketamine: Investigating metabolite contribution to subjective effects

Marije E Otto iD, Gabriël E Jacobs, Joost C van Mechelen iD, Laura G J M Borghans iD, Johan G C van Hasselt, Linda B S Aulin

British Journal of Clinical Pharmacology · 2026-07 · 92 (7) · 2260-2271

DOI: 10.1002/bcp.70503 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift British Journal of Clinical Pharmacology, online erschienen am 06.03.2026. Verfasst von Marije E Otto und 5 weiteren Autor:innen. Beteiligte Einrichtung: Centre for Human Drug Research (CHDR), Leiden, the Netherlands. Hauptthemen laut MEDLINE: Antidepressive Agents, Ketamine. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 53 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Centre for Human Drug Research.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Aims

Oral administration of (S)‐ketamine for treatment‐resistant depression (TRD), as alternative to the registered intranasal or off‐label intravenous administrations, has high potential. However, it is characterized by an extensive first‐pass metabolism, resulting in low (S)‐ketamine exposure and high levels of active metabolites, including (S)‐norketamine and (S)‐hydroxynorketamine. The relative contribution of the parent and metabolites to the resulting antidepressant effects remains unclear. Therefore, this study aimed to first characterize the pharmacokinetics (PK) of (S)‐ketamine and its metabolites after oral and intravenous administration in healthy participants and secondly quantify the pharmacokinetic/pharmacodynamic (PKPD) relationship of (S)‐ketamine and (S)‐norketamine to the subjective effects measured on the visual analogue scale (VAS) ‘Feeling High’.

Methods

Data from a previously conducted clinical study was used, where 17 healthy participants received oral (0.20 and 0.45 mg/kg) and intravenous (0.4 mg/kg over 40 min) (S)‐ketamine in a randomized, placebo‐controlled, crossover clinical trial. A semi‐physiological population PK model was developed to describe the first‐pass metabolism and (S)‐ketamine and subsequently (S)‐norketamine concentrations were linked to the VAS ‘Feeling High’ using a bounded integer modelling approach.

Results

A significant (S)‐norketamine PKPD relationship was determined alongside (S)‐ketamine, but estimated variance of the bounded integer model was high warranting further investigation.

Conclusions

Our analysis suggests that not (S)‐ketamine, but its metabolite, is the main driver of subjective effects after oral administration, and as such may also contribute to antidepressant effects in TRD patients receiving oral (S)‐ketamine.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antidepressive AgentsKetamineAdultFemaleHumansMaleYoung AdultAdministration, IntravenousAdministration, OralCross-Over StudiesDose-Response Relationship, DrugDouble-Blind Method

Stichwörter der Autor:innen

PKPD modelketaminenorketaminepharmacodynamicspharmacokineticssubjective effects

Substanzen

Antidepressive AgentsKetaminenorketamine

Autor:innen und Institutionen

  • Centre for Human Drug Research (CHDR), Leiden, the Netherlands.
  • Leiden Academic Centre for Drug Research (LACDR), Leiden University, Leiden, the Netherlands.
  • Leiden University Medical Centre (LUMC), Leiden, the Netherlands.

ORCID-Profile: Marije E Otto, Joost C van Mechelen, Laura G J M Borghans

Förderung

  • Centre for Human Drug Research

Zitieren

APA

Otto, M. E., Jacobs, G. E., van Mechelen, J. C., Borghans, L. G. J. M., van Hasselt, J. G. C., & Aulin, L. B. S. (2026). Pharmacokinetics and pharmacodynamics of intravenous and oral (S)‐ketamine: Investigating metabolite contribution to subjective effects. British Journal of Clinical Pharmacology, 92(7), 2260-2271. https://doi.org/10.1002/bcp.70503

Vancouver

Otto ME, Jacobs GE, van Mechelen JC, Borghans LGJM, van Hasselt JGC, Aulin LBS. Pharmacokinetics and pharmacodynamics of intravenous and oral (S)‐ketamine: Investigating metabolite contribution to subjective effects. British Journal of Clinical Pharmacology. 2026;92(7):2260-2271. doi:10.1002/bcp.70503

BibTeX
@article{Otto2026,
  author = {Otto, Marije E and Jacobs, Gabriël E and van Mechelen, Joost C and Borghans, Laura G J M and van Hasselt, Johan G C and Aulin, Linda B S},
  title = {Pharmacokinetics and pharmacodynamics of intravenous and oral (S)‐ketamine: Investigating metabolite contribution to subjective effects},
  journal = {British Journal of Clinical Pharmacology},
  year = {2026},
  volume = {92},
  number = {7},
  pages = {2260--2271},
  doi = {10.1002/bcp.70503}
}
Kostenlos starten →